Erratum: Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder (Urology (2010) 76, (1350-1357) DOI: 10.1016/j.urology.2010.03.097);Efficacy and tolerability of fesoterodine in older and younger subjects with overactive bladder

Urology

Volumn 76, Issue 6, 2010, Pages 1350-1357

  Kraus, Stephen R ^a   Ruiz Cerd, Jos Luis ^b   Martire, Diane ^c   Wang, Joseph T ^c   Wagg, Adrian S ^d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b HOSPITAL UNIVERSITARIO LA FE   (Spain)

^c PFIZER INC   (United States)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FESOTERODINE; PLACEBO;

ADULT; AGED; ARTICLE; BALANCE DISORDER; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY THROAT; DYSPEPSIA; EPISTAXIS; FEMALE; HEADACHE; HUMAN; INFLUENZA; KING HEALTH QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; MICTURITION; NAUSEA; OVERACTIVE BLADDER; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINOPHARYNGITIS; SINUSITIS; TOOTH PAIN; TREATMENT BENEFIT SCALE; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URGE INCONTINENCE; URINARY TRACT INFECTION; URINE RETENTION; URINE VOLUME; XEROSTOMIA;

EID: 78649906797     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.12.038     Document Type: Erratum

References (30)

1. P. Abrams, L. Cardozo, and M. Fall The standardisation of terminology in lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society Urology. 61 2003 37 49
2. B.T. Haylen, D. de Ridder, and R.M. Freeman An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction Neurourol Urodyn. 29 2010 4 20
3. D.E. Irwin, I. Milsom, and S. Hunskaar Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study Eur Urol. 50 2006 1306 1315
4. J.F. Wyman, K.L. Burgio, and D.K. Newman Practical aspects of lifestyle modifications and behavioural interventions in the treatment of overactive bladder and urgency urinary incontinence Int J Clin Pract. 63 2009 1177 1191
5. C.R. Chapple, V. Khullar, and Z. Gabriel The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis Eur Urol. 54 2008 543 562
6. K.L. Burgio, J.L. Locher, and P.S. Goode Combined behavioral and drug therapy for urge incontinence in older women J Am Geriatr Soc. 48 2000 370 374
7. C.G. Klutke, K.L. Burgio, and J.F. Wyman Combined effects of behavioral intervention and tolterodine in patients dissatisfied with overactive bladder medication J Urol. 181 2009 2599 2607
8. C. Chapple, P. Van Kerrebroeck, and A. Tubaro Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder Eur Urol. 52 2007 1204 1212
9. V.W. Nitti, R. Dmochowski, and P.K. Sand Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome J Urol. 178 2007 2488 2494
10. M.C. Michel Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome Expert Opin Pharmacother. 9 2008 1787 1796
11. B.K. Malhotra, N. Wood, and R. Sachse Influence of age, gender, and race on pharmacokinetics, pharmacodynamics, and safety of fesoterodine Int J Clin Pharmacol Ther. 47 2009 570 578
12. B. Malhotra, R. Sachse, and N. Wood Evaluation of drugdrug interactions with fesoterodine Eur J Clin Pharmacol. 65 2009 551 560
13. Toviaz (fesoterodine fumarate): full prescribing information 2008 Pfizer Inc New York
14. de Mey C, Mateva L, Krastev Z, et al. Effects of hepatic dysfunction on the single-dose pharmacokinetics of fesoterodine. J Clin Pharmacol. Epub 2010 April 6.
15. B. Malhotra, K. Gandelman, and R. Sachse Assessment of the effects of renal impairment on the pharmacokinetic profile of fesoterodine J Clin Pharmacol. 49 2009 477 482
16. A.A. Mangoni, and S.H. Jackson Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications Br J Clin Pharmacol. 57 2004 6 14
17. J.B. Schwartz The current state of knowledge on age, sex, and their interactions on clinical pharmacology Clin Pharmacol Ther. 82 2007 87 96
18. A.S. Wagg, L. Cardozo, and C. Chapple Overactive bladder syndrome in older people BJU Int. 99 2007 502 509 (Pubitemid 46238818)
19. J.G. Malone-Lee, J.B. Walsh, and M.F. Maugourd Tolterodine: a safe and effective treatment for older patients with overactive bladder J Am Geriatr Soc. 49 2001 700 705
20. M.C. Michel, T. Schneider, and S. Krege Does gender or age affect the efficacy and safety of tolterodine? J Urol. 168 2002 1027 1031
21. N.R. Zinner, A. Mattiasson, and S.L. Stanton Efficacy, safety, and tolerability of extended-release once-daily tolterodine treatment for overactive bladder in older versus younger patients J Am Geriatr Soc. 50 2002 799 807
22. C. Chapple, C. DuBeau, and U. Ebinger Darifenacin treatment of patients >or= 65 years with overactive bladder: results of a randomized, controlled, 12-week trial Curr Med Res Opin. 23 2007 2347 2358
23. A. Wagg, J.J. Wyndaele, and P. Sieber Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis Am J Geriatr Pharmacother. 4 2006 14 24
24. P.R. Reese, A.M. Pleil, and G.J. Okano Multinational study of reliability and validity of the King's Health Questionnaire in patients with overactive bladder Qual Life Res. 12 2003 427 442
25. S. Colman, C. Chapple, and V. Nitti Validation of treatment benefit scale for assessing subjective outcomes in treatment of overactive bladder Urology. 72 2008 803 807
26. V.F. Schabert, T. Bavendam, and E.L. Goldberg Challenges for managing overactive bladder and guidance for patient support Am J Manag Care. 15 2009 S118 S122
27. A. Wagg, A. Fahey, and E. Siddiqui Persistence with oral antimuscarinics used for the treatment of overactive bladder in different age groups of patients in general practice Age Ageing. 39 suppl 1 2010 i37
28. M.S. Choo, C. Song, and J.H. Kim Changes in overactive bladder symptoms after discontinuation of successful 3-month treatment with an antimuscarinic agent: a prospective trial J Urol. 174 2005 201 204 (Pubitemid 40825714)
29. S.A. Kaplan, K. Walmsley, and A.E. Te Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia J Urol. 174 2005 2273 2276
30. P. Abrams, S.A. Kaplan, and H.J. De Koning Gans Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction J Urol. 175 2006 999 1004